Cholangiocarcinoma: Clinical Trials

343 trials for Cholangiocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

108 completed, 70 recruiting, 51 unknown, 44 terminated. 343 Phase 2, 58 Phase 1, 17 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2343Completed 108, Recruiting 70, Unknown 51, Terminated 44, Active not recruiting 32, Not yet recruiting 21, Withdrawn 12, Enrolling by invitation 3, Suspended 2
Phase 158Completed 18, Recruiting 13, Terminated 12, Unknown 9, Active not recruiting 3, Not yet recruiting 2, Enrolling by invitation 1
Phase 317Unknown 5, Active not recruiting 4, Recruiting 4, Not yet recruiting 2, Terminated 2

Follow Cholangiocarcinoma: new trials by email Literature Review of Cholangiocarcinoma trials Research Report on Cholangiocarcinoma

Trials (filtered) newest first · largest first

All 343 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
Tislelizumab - Cholangiocarcinoma, Biliary Tract Cancer (BTC)
Phase 2Not yet recruitingNational Cheng-Kung University Hospital352027-06-012026-11-17
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group3362027-01-112026-08-14
A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy
Pemigatinib - Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma
Phase 2Not yet recruitingIncyte Corporation722026-12-152026-10-20
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
3D185 - Cholangiocarcinoma,Adult
Phase 2Not yet recruiting3D Medicines (Beijing) Co., Ltd.502026-12-012026-09-09
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
[225Ac]Ac-FL-261 - Solid Tumor, NSCLC
Phase 1 / Phase 2RecruitingFull-Life Technologies UK Limited2082026-12-012026-11-16
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma
Phase 2RecruitingOhio State University Comprehensive Cancer Center292026-11-012026-09-10
Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma
Histotripsy, Durvalumab, Biopsy - Intrahepatic Cholangiocarcinoma
Phase 2RecruitingUniversity of Wisconsin, Madison122026-11-012026-10-30
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc)
Phase 2Not yet recruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins552026-11-012026-11-10
[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma
Computed Tomography, Fluorine F 18 Fluorthanatrace, Magnetic Resonance Imaging - Cholangiocarcinoma
Phase 2RecruitingUniversity of Washington222026-10-082026-10-20
Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma
Anlotinib, TQB2868 Injection, cryoablation - Intrahepatic Cholangiocarcinoma
Phase 2Not yet recruitingFudan University562026-10-012026-09-29
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin - Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy
Phase 2RecruitingThe First Affiliated Hospital with Nanjing Medical University812026-09-302026-10-28
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
Celecoxib + Pembrolizumab + Gemcitabine/Cisplatin, Pembrolizumab + Gemcitabine/Cisplatin - Intrahepatic Cholangiocarcinoma (Icc)
Phase 1 / Phase 2Not yet recruitingShanghai 6th People's Hospital1122026-09-152026-08-28
A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
VG2025 - Intrahepatic Cholangiocarcinoma
Phase 2RecruitingVirogin Biotech Ltd.302026-08-252026-09-22
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
FGFR Inhibitor, IDH1 mutation inhibitor, KRAS mutation inhibitor - Bile Duct Carcinoma, Cholangiocarcinoma
Phase 2Not yet recruitingZhejiang University2402026-08-102026-07-28
Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study
Postoperative radiotherapy, Capecitabine or S-1 - Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences922026-06-162026-06-24
HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC
hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab - Intrahepatic Cholangiocarcinoma
Phase 2RecruitingLianghe Lu352026-06-112026-09-25
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
GV20-0251, anti-PD-1 monoclonal antibodies - Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
Phase 2Not yet recruitingGV20 Therapeutics2272026-06-022026-06-08
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test - Foregut Adenocarcinoma, Esophageal Adenocarcinoma
Phase 2RecruitingYale University542026-06-022026-09-08
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
Becotatug Vedotin, Pucotenlimab, Gemcitabine - Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingSir Run Run Shaw Hospital1642026-05-202026-05-20
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
ASP546C - Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Phase 1 / Phase 2RecruitingAstellas Pharma Global Development, Inc.1502026-05-042026-11-13

Showing 20 of 343. Sign in to see all of them.

Narrower conditions

Gallbladder Neoplasms (61)  ·  Biliary Tract Neoplasms (56)  ·  Bile Duct Neoplasms (36)  ·  Colorectal Neoplasms (27)  ·  Carcinoma, Hepatocellular (26)  ·  Pancreatic Neoplasms (25)  ·  Stomach Neoplasms (22)  ·  Cirrhosis, Familial, with Pulmonary Hypertension (19)  ·  Liver Neoplasms (19)  ·  Klatskin Tumor (18)  ·  Breast Neoplasms (17)  ·  Carcinoma, Non-Small-Cell Lung (17)  ·  Neoplasm Metastasis (17)  ·  Ovarian Neoplasms (16)

Broader conditions

Neoplasms by Histologic Type (343)  ·  Neoplasms, Glandular and Epithelial (343)  ·  Adenocarcinoma (341)  ·  Carcinoma (335)  ·  Neoplasms (329)  ·  Neoplasms by Site (162)  ·  Digestive System Diseases (155)  ·  Digestive System Neoplasms (153)  ·  Biliary Tract Diseases (110)  ·  Gallbladder Diseases (61)  ·  Biliary Tract Neoplasms (54)  ·  Gastrointestinal Diseases (47)  ·  Endocrine Gland Neoplasms (41)  ·  Endocrine System Diseases (41)  ·  Gastrointestinal Neoplasms (41)

Interventions

Gemcitabine (77)  ·  Cisplatin (47)  ·  Oxaliplatin (32)  ·  durvalumab (24)  ·  Capecitabine (23)  ·  Fluorouracil (22)  ·  pembrolizumab (22)  ·  lenvatinib (21)  ·  Leucovorin (15)  ·  Magnetic Resonance Spectroscopy (11)  ·  Specimen Handling (11)  ·  tislelizumab (11)  ·  130-nm albumin-bound paclitaxel (9)  ·  Biopsy (9)  ·  Drug Therapy (9)

Sponsors

National Cancer Institute (NCI) (19)  ·  Shanghai Zhongshan Hospital (11)  ·  Fudan University (10)  ·  Tianjin Medical University Cancer Institute and Hospital (9)  ·  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (7)  ·  Peking Union Medical College Hospital (5)  ·  Sun Yat-sen University (5)  ·  The First Affiliated Hospital with Nanjing Medical University (5)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  University of Zurich (4)  ·  AIO-Studien-gGmbH (3)  ·  Asan Medical Center (3)  ·  Hoffmann-La Roche (3)  ·  Incyte Corporation (3)  ·  M.D. Anderson Cancer Center (3)

Countries

United States (133)  ·  China (109)  ·  South Korea (33)  ·  France (28)  ·  Germany (28)  ·  Italy (24)  ·  Spain (23)  ·  Taiwan (19)  ·  Australia (17)  ·  Canada (17)  ·  Netherlands (17)  ·  United Kingdom (17)  ·  Belgium (15)  ·  Japan (11)  ·  Denmark (8)

Top investigators

Peng Wang, MD (4)  ·  Jonathan M Hernandez, M.D. (3)  ·  Tim F Greten, M.D. (3)  ·  Benjamin Tan, M.D. (2)  ·  Feng Cheng, MD (2)  ·  Hai-Tao Zhao, M.D. (2)  ·  Jia Fan, MD & PhD (2)  ·  Jian Zhou, MD & PhD (2)  ·  Jian Zhou, MD&PhD (2)  ·  Jordi Bruix, MD (2)  ·  Nilofer S Azad (2)  ·  Patricia M LoRusso (2)

Results publications

PMID 40812353, PMID 20375404, PMID 29433850, PMID 30998813, PMID 24146220, PMID 27095655, PMID 28818953, PMID 30420614, PMID 32461347, PMID 33198671, PMID 15192785, PMID 15319238, PMID 17543307, PMID 18751418, PMID 18981929, PMID 19097774, PMID 19491285, PMID 19626372, PMID 20014463, PMID 20165987, PMID 20662793, PMID 20678012, PMID 22261548, PMID 22367707, PMID 22537432, PMID 22762399, PMID 23043667, PMID 23480759, PMID 23846786, PMID 24461131, PMID 24581682, PMID 24681130, PMID 24769639, PMID 24852116, PMID 25095718, PMID 25111859, PMID 25538178, PMID 25632066, PMID 25738477, PMID 25763789, PMID 25899049, PMID 25937868, PMID 26179201, PMID 26487951, PMID 26540314, PMID 26598942, PMID 26695839, PMID 27114433, PMID 27234522, PMID 27627808

NIH funding

2023 (7), 2015 (4), 2016 (4), 2025 (4), 2019 (2), P30CA138292 (2), U10CA032102 (2), U10CA180820 (2), U10CA180888 (2), UM1CA186689 (2), UM1CA186691 (2), 2009 (1), 2014 (1), 2017 (1), 2018 (1)